NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)
ID: 357036Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/357036

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-25-049.html
Timeline
    Description

    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required), aimed at supporting multi-center clinical trials focused on neurological emergencies such as status epilepticus and traumatic brain injury. This initiative encourages collaboration with the NIH SIREN Clinical Coordinating Center to ensure efficient trial implementation, while applicants are expected to provide rigorous preclinical data and compelling rationales for their proposed interventions. The funding opportunity operates under a phased mechanism, with UG3 for planning and UH3 for execution, reflecting a commitment to enhance clinical research in emergency care. Interested applicants can find more information and application guidelines at the provided link, with a submission deadline of March 6, 2026, and no cost-sharing or matching requirements.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-25-049.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), has issued a Notice of Funding Opportunity (NOFO) titled NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required). This funding initiative encourages applications for multi-center clinical trials aimed at addressing neurological emergencies, such as status epilepticus and traumatic brain injury, under the Strategies to Innovate Emergency Care Clinical Trials Network (SIREN). Successful applicants will collaborate with the NIH SIREN Clinical Coordinating Center for efficient trial implementation while adhering to specific guidelines regarding application preparation and submission. The NOFO provides critical application timelines, eligibility criteria, and detailed information on project phases, promoting innovative trial designs and rigorous scientific standards. The funding opportunity operates under a phased mechanism (UG3 for planning stages and UH3 for execution), requiring evidence of rigorous preclinical data and compelling rationales for proposed interventions. The collaboration with NIH aims to consolidate expertise in emergency care, improving outcomes in neurological and cardiovascular emergencies. Overall, this NOFO reflects a significant commitment by federal agencies to enhance clinical research in emergency care by leveraging existing infrastructure and fostering collaborations across various institutions.
    Similar Opportunities
    NIH SIREN Neurologic Clinical Trials (UG3/UH3 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the SIREN Neurologic Clinical Trials (UG3/UH3), aimed at developing multi-center clinical trials focused on neurological emergencies. This initiative encourages applications from a diverse range of entities, including universities, nonprofit organizations, and various community-serving institutions, to utilize the SIREN Network's infrastructure for efficient trial management, statistical support, and patient recruitment. The overarching goal is to enhance understanding and treatment of neurological emergencies through collaborative clinical research, ultimately improving patient outcomes and advancing healthcare practices. Interested applicants should note that the application deadline is March 6, 2026, and can find further details and guidelines at the provided NIH link or contact grantsinfo@nih.gov for inquiries.
    NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for the NIH StrokeNet Clinical Trials and Biomarker Studies aimed at enhancing stroke treatment, recovery, and prevention strategies. This initiative invites applications for multi-site exploratory and confirmatory clinical trials, as well as biomarker validation studies and ancillary studies linked to ongoing StrokeNet projects, with a focus on innovative interventions and patient-centric designs. The funding is structured as a cooperative agreement (UG3/UH3), allowing for initial support of one year with the potential for six additional years based on milestone achievements. Interested applicants, including academic institutions, nonprofits, and government agencies, must adhere to specific submission guidelines and deadlines, with applications due by November 19, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-25-052.html.
    NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "NINDS Efficacy and Exploratory Clinical Trials (UG3/UH3 - Clinical Trial Required)" aimed at soliciting applications for research on exploratory and efficacy clinical trials that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS). This initiative will focus on evaluating various interventions, including drugs, biologics, devices, and therapies related to surgical, behavioral, and rehabilitation approaches. The opportunity is particularly significant for researchers with expertise in neurological disorders, as it encourages the development of meaningful collaborations and responsive projects in this critical health area. Interested applicants can reach out to Jeremy Brown, MD, via email at ExploratoryEfficacyTrials@ninds.nih.gov for further information, with the estimated synopsis posting date set for November 12, 2025, and applications expected to close by February 10, 2026.
    NeuroNEXT Small Business Innovation in Clinical Trials (U44 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NeuroNEXT Small Business Innovation in Clinical Trials," aimed at encouraging small businesses to conduct exploratory clinical trials of investigational agents related to neurological disorders. This initiative seeks applications for Phase II Small Business Innovation Research (SBIR) projects, with a budget of up to $3 million over five years, focusing on trials that align with the strategic plan of the National Institute of Neurological Disorders and Stroke (NINDS). The program is designed to foster public-private partnerships to enhance the development and commercialization of innovative therapies, ultimately improving clinical outcomes in neuroscience research. Interested applicants must adhere to a Community Engagement and Research Inclusion (CERI) plan, with the first application deadline set for January 5, 2025, and additional deadlines throughout 2026 and 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) through the NINDS Exploratory Clinical Trials program (R43/R44), aimed at supporting investigator-initiated exploratory clinical trials related to neurological disorders. This program invites applications for studies that evaluate drugs, biologics, devices, or therapies, generating preliminary data to inform future clinical development, with a focus on enhancing diverse perspectives within research teams. Eligible U.S.-based SBCs can apply for funding caps of up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by September 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html.
    BRAIN Initiative: Clinical Studies to Advance Next-Generation Devices for Recording and Modulation in the Human Central Nervous System (UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for clinical studies aimed at advancing next-generation devices for recording and modulation in the human central nervous system, under the BRAIN Initiative. This initiative seeks to support small clinical trials that provide critical data necessary for the development of devices intended to treat central nervous system disorders, particularly those requiring an Investigational Device Exemption (IDE) from the FDA. The funding is crucial for enhancing neurotechnology and improving treatment outcomes, with NIH planning to allocate approximately $10 million annually for 5 to 7 awards, each with a maximum budget of $1.5 million per year for up to five years. Interested applicants can find more information and submit inquiries via grantsinfo@nih.gov, with applications due by September 28, 2026.
    Investigate Novel Therapeutic Interventions and Testing Strategies for Neurological Disorders Including to Treat, Modify and Prevent the Development of Epilepsy (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for research aimed at investigating novel therapeutic interventions and testing strategies for neurological disorders, specifically targeting the treatment, modification, and prevention of epilepsy. This initiative encourages applicants to explore various intervention modalities and develop human-focused testing approaches, with a particular emphasis on preclinical therapy testing and model development. The total estimated program funding is $6.2 million, with individual awards ranging from $3.5 million to $4 million, and the application process is expected to open with a synopsis posted by December 19, 2025, closing on February 20, 2026. Interested applicants can reach out to Dr. Brian Klein at brian.klein@nih.gov or (301) 496-0981 for further information.
    NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "NIH StrokeNet Clinical Trials and Biomarker Studies for Stroke Treatment, Recovery, and Prevention (UG3/UH3 Clinical Trial Optional)." This initiative aims to support multi-site exploratory and confirmatory clinical trials that focus on innovative interventions, biomarker validation, and ancillary studies related to stroke prevention, treatment, and recovery. The program emphasizes collaboration within the NIH StrokeNet infrastructure to enhance patient recruitment and trial execution, addressing critical public health issues associated with stroke. Interested applicants must submit their proposals by November 19, 2026, and can find additional information and application details at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    NIAID Clinical Trial Implementation Cooperative Agreement (U01 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a Notice of Funding Opportunity (NOFO) for the NIAID Clinical Trial Implementation Cooperative Agreement (U01), aimed at supporting high-risk clinical trials that enhance the understanding of human diseases. This funding opportunity encourages applications for investigator-initiated, milestone-driven clinical trials, with each application permitted to propose only one clinical trial that must demonstrate a hypothesis-driven approach. The initiative emphasizes the importance of mechanistic studies within clinical trials and requires a robust plan for managing trial complexity and participant safety. Interested applicants can find additional details and guidelines at the provided NIH link, with the earliest submission date set for April 12, 2024, and the application deadline on January 13, 2027. For inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov.